Artemisinin is rapidly metabolized in the liver into active metabolites, primarily via the cytochrome P450 pathway. Its half-life is relatively short, necessitating frequent dosing to maintain therapeutic levels. The rapid metabolism and elimination could contribute to its low toxicity profile, but also highlight the importance of adherence to dosing schedules to ensure efficacy.
